Pitavastatin decreases serum LOX-1 ligand levels and MT1-MMP expression in CD14-positive mononuclear cells in hypercholesterolemic patients

Saved in:
Bibliographic Details
Published inInternational journal of cardiology Vol. 176; no. 3; pp. 1230 - 1232
Main Authors Uzui, Hiroyasu, Hayashi, Hideki, Nakae, Izuru, Matsumoto, Tetsuya, Uenishi, Hiroaki, Hayasaki, Hisae, Asaji, Takayoshi, Matsui, Shinobu, Miwa, Kunihisa, Lee, Jong-Dae, Tada, Hiroshi, Sawamura, Tatsuya, Fujita, Masatoshi
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ireland Ltd 20.10.2014
Subjects
Cardiovascular
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Hypercholesterolemia - immunology
Leukocytes, Mononuclear - immunology
Ligands
Lipopolysaccharide Receptors - immunology
LOX-1 ligand
Male
Matrix Metalloproteinase 14 - biosynthesis
Middle Aged
MT1-MMP
Pitavastatin
Plaque vulnerability
Quinolines - therapeutic use
Scavenger Receptors, Class E - blood
Pitavastatin
Plaque vulnerability
MT1-MMP
LOX-1 ligand
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2014.07.213